ESR1 and breast carcinoma: More than 25% of ERα(−) breast cancer cells have aberrant methylation of the ERα promoter and histone acetylation/deacetylation have also been implicated as common mechanisms for ERα gene transactivation/repression in human breast cancer cells27, 28.